Aimmune Therapeutics, Inc.: Aimmune Therapeutics to Present New Data for PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022

Analysis to be Presented Showed Peanut Allergy Treatment with PALFORZIA was Associated with Improvements in Health-Related Quality of Life among Patients and Caregivers -Additional Data to be Presented

Related Keywords

Prague ,Praha ,Hlavníesto ,Czech Republic ,Switzerland ,Kostenloser Wertpapierhandel ,Lauren Barbiero ,Audrey Dunn Galvin ,A Dunn Galvin ,Stephen Tilles ,Aimmune Therapeutics Inc ,Health Science Company ,Health Science ,University College Cork ,European Commission ,Drug Administration ,Health Science Nhsc ,Global Head Of Medical Affairs ,Regulatory Agency ,Improvements In Health ,European Academy Of Allergy ,Presented Showed Peanut Allergy Treatment ,Health Related Quality ,Additional Data ,European Academy ,Clinical Immunology ,Hybrid Congress ,Senior Medical Director ,Global Head ,Medical Affairs ,Pediatric Psychologist ,Presented Include ,Related Quality ,Life Reported ,Food Allergy Quality ,Life Questionnaire ,Food Allergy Independent Measure ,Peanut Allergy ,Results From Clinical ,Treatment Satisfaction Questionnaire ,Safety Information ,Prescribing Information ,Medication Guide ,Dose Escalation ,Initial Dose Escalation ,Risk Evaluation ,Mitigation Strategy ,Aimmune ,Herapeutics ,Present ,Data ,Palforzia ,Peanut ,Karachis ,Ypogaea ,Llergen ,Powder ,Nfp ,Caaci ,Hybrid ,Congress ,022 ,